ROCHESTER, Minn., July 18 (UPI) -- Certolizumab pegol effectively treats the symptoms of Crohn’s disease and produced a nearly 50-percent remission rate at six months, says a U.S. study. Mayo Clinic researcher William Sandborn led the two-armed study, which is the first clinical trial for Crohn’s disease to run longer than 12 weeks.
